An abstract titled, “Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT,” was published in the Journal of Clinical Oncology and presented at the American Society of Clinical Oncology (ASCO) 2023 Poster Session at the 2024 by authors Ye Yuan, Gavin Hui, Saurabh Gombar, and Nima Aghdam. Dr. Aghdam is affiliated with Beth Israel Deaconess Medical Center, Boston, MA, and Dr. Gombar, Dr. Hui, and Dr. Yuan are affiliated with Atropos Health.
Short Summary:
This study aimed to investigate the association between short-term (ST-ADT) and long-term androgen deprivation therapy (LT-ADT) in patients with localized prostate cancer and the risk of major adverse cardiac events (MACE). The study queried a large, nationally representative electronic health record dataset to identify patients with prostate cancer who received ADT.
Key Conclusions:
- In a national dataset analysis of patients with local PrCa and no history of MACE or abiraterone or docetaxel within 3 months of diagnosis LT-ADT was associated with increased odds of CAD but there was no difference in the composite endpoint of MACE or metastatic recurrence.
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com